Clinical Trials Browser

Phase 3 × Active not recruiting × enzalutamide × Clear all

NCT04076059 2026-04-17

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT03395197 2026-04-07

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

Phase 3 Active not recruiting

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT02194842 2025-09-19

PEACE III

Phase 3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 2 FDA

Prostatic Neoplasms

NCT02446444 2025-05-30

ENZARAD

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

Prostatic Neoplasms